S. M. Boer

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

H. Putter, T. Bosse, B. van Triest, 2018, British Journal of Cancer.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

H. Putter, C. Haie-meder, D. Katsaros, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

C. Haie-meder, P. Pollock, H. Mackay, 2019, Annals of Oncology.